Zacks Investment Research on MSN7d
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...
Zacks Investment Research on MSN6d
Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide). This ...
2don MSN
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...
Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback